SSII is rapidly growing its surgical robotics business, with strong revenue and KPI growth while expanding into new international markets. Despite operating losses and dilution risk, I see a path to profitability as installations and instrument sales accelerate. The stock is aggressively valued, but industry-leading growth and sector hype justify a speculative buy for risk-tolerant investors.
Surgery performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador PR Audio: Fort Lauderdale, FL, June 16, 2025 – PRISM MediaWire – SS Innovations International, Inc.
SS Innovations Announces Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company's SSi Mantra 3 Surgical Robotic System
FORT LAUDERDALE, Fla., May 27, 2025 – PRISM MediaWire – SS Innovations International, Inc.
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company's SSi Mantra surgical robotic system has been utilized to successfully perform more than 4,000 robotic surgeries across more than one hundred types of surgeries without any complications, injuries or mortalities.
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 Fort Lauderdale, FL, May 14, 2025 – PRISM MediaWire – SS Innovations International, Inc.
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025.
All Clinical Data Validated by Leading Third-Party CRO for Safety, Feasibility and Efficacy FORT LAUDERDALE, Fla., May 08, 2025 – PRISM MediaWire – SS Innovations International, Inc.
Press Audio Overview: FORT LAUDERDALE, Fla., May 05, 2025 – PRISM MediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025.
FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025.
FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition.
Listened: Thomas Wolff · SS Innovations Announces Chief Financial Officer Transition Fort Lauderdale, FL, May 2, 2025 – PRISM MediaWire – SS Innovations International, Inc.